Abstract
Enhanced growth inhibition and antitumor responses to adriamycin have been observed repeatedly from several laboratories using impermeant forms of adriamycin where entry into the cell was greatly reduced or prevented. Our laboratory has described an NADH oxidase activity at the external surface of plasma membrane vesicles from tumor cells where inhibition by an antitumor sulfonylurea, N-(4-methylphenylsulfonyl)-N′-(4-chlorophenyl)urea (LY181984), and by the vanilloid, capsaicin (8-methyl-N-vanillyl-6-noneamide) correlated with inhibition of growth. Here we report that the oxidation of NADH by isolated plasma membrane vesicles was inhibited, as well, by adriamycin. An external site of inhibition was indicated from studies where impermeant adriamycin conjugates were used. The EC50 for inhibition of the oxidase of rat hepatoma plasma membranes by adriamycin was several orders of magnitude less than that for rat liver. Adriamycin cross-linked to diferric transferrin and other impermeant supports also was effective in inhibition of NADH oxidation by isolated plasma membrane vesicles and in inhibition of growth of cultured cells. The findings suggest the NADH oxidase of the plasma membrane as a growth-related adriamycin target at the surface of cancer cells responsive to adriamycin. Whereas DNA intercalation remains clearly one of the principal bases for the cytotoxic action of free adriamycin, this second site, possibly related to a more specific antitumor action, may be helpful in understanding the enhanced efficacy reported previously for immobilized adriamycin forms compared to free adriamycin.
Similar content being viewed by others
REFERENCES
Adler, R., Hurwitz, E., Wands, J. R., Sela, M., and Shoural, D. (1995). Hepatology 22, 1482–1487.
Alegria, A. E., Rodriguez, M. S., and Hernandez, J. (1990). Biochim. Biophys. Acta 1035, 51–55.
Arcomone, F. (1985). Cancer Res. 45, 5995–5999.
Bachur, H. R., Gordon, S. L., Gee, M. V., and Kon, H. (1979). Proc. Natl. Acad. Sci. USA 76, 954.
Barabas, K., Sizensky, J. A., and Faulk, W. P. (1991). Am. J. Reprod. Immunol. 25, 120–123.
Barabas, K., Sizensky, J. A., and Faulk, W. P. (1992). J. Biol. Chem. 267, 9437–9442.
Bérczi, A., Barabas, K., Sizensky, J. A., and Faulk, W. P. (1993). Arch. Biochem. Biophys. 300, 356–363.
Brightman, A. O., Wang, J., Miu, R. K., Sun, I. L., Barr, R., Crane, F. L., and Morré, D. J. (1992). Biochim. Biophys. Acta 1105, 109–117.
Bruno, M., Brightman, A. O., Lawrence, J., Werderitsh, D., Morré D. M., and Morré, D. J. (1992). Biochem. J. 284, 625–628.
Bucher, J., Tien, M., Morehouse, L., and Aust, S. (1983). Fundam. Appl. Toxicol. 3, 222–226.
Deliconstantinos, G. (1987). Anticancer Res. 7, 1011–1022.
Dillman, R. O., Shawler, D. L., Johnson, D. E., Meyer, D. L., Koziol, J. A., and Frincke, J. M. (1986). Cancer Res. 46, 4886–4891.
Doroshow, J. (1983). Cancer Res. 43, 4543–4551.
Faulk, W. P., Hsi, B. L., and Stevens, P. J. (1980). Lancet 2, 390–392.
Faulk, W. P., Taylor, C. G., Yeh, C. J. G., and McIntyre, J. A. (1990a). Mol. Biotherm. 2, 57–60.
Faulk, W. P., Harats, H., and Bérczi, A. (1990b). In Oxidoreduction at the Plasma Membrane: Growth and Transport. I. Animals (Crane, F. L., Morré, D. J., and Löw, H. eds.), CRC Press, Boca Raton, Florida, pp. 205–224.
Faulk, W. P., Barabas, K., Sun, I. L., and Crane, F. L. (1991). Biochem. Int. 25, 815–822.
Fritzer, M., Barabas, K., S\({\ddot z}\)uts, V., Bérczi, A., Szekeres, R., Faulk, W. P., and Goldenberg, H. (1992). Int. J. Cancer 52, 619–623.
Goldman, R., Facchine, H. T., Bach, D., Ray, A., and Shinitzky, M. (1976). Biochim. Biophys. Acta 512, 254–269.
Goormaghtigh, E., Pollakis, G., and Ruysschaert, R. (1983). Biochem. Pharmacol. 32, 889–893.
Haidle, C., and McKinney, S. (1986). Cancer Biochim. Biophys. 515, 327–335.
Jadot, G. (1986). Free Rad. Res. Commun. 139, 1117–1123.
Kaneko, T., Willner, D., Monkovic, I., Knipe, J. O., Braslawsky, G. R., Greenfield, R. S., and Vyas, D. M. (1991). Bioconjug. Chem. 2, 133–141.
Kim, C., MacKellar, W. C., Cho, N., Byrn, S. R., and Morré, D. J. (1997). Biochim. Biophys. Acta, 1324, 171–181.
Kloppel, T. M., and Morré, D. J. (1980). J. Natl. Cancer Inst. 64, 1401–1411.
Komazawa, H., Fuji, H., Kojima, M., Mori, H., Ono, M., Itoh, I., Azuma, I., and Saiki, I. (1995). Oncol. Res. 7, 341–351.
Löw, H., and Crane, F. L. (1978). Biochim. Biophys. Acta 515, 141–161.
Löw, H., Sun, I. L., Navas, P., Grebing, C., Crane, F. L., and Morré, D. J. (1986). Biochem. Biophys. Res. Commun. 139, 1117–1123.
Lutter, R., van Zweiten, R., Weening, R. S., Hamars, M. N., and Roos, D. (1984). J. Biol. Chem. 259, 9603–9606.
McCay, P., Fong, K., King, M., Lai, E., Weddle, C., Poyer, L., and Hornbrook, K. (1976). In Lipids, Vol. I, Raven Press, New York, pp. 157–168.
Minow, R. A., Benjamin, R. S., and Gottliev, J. A. (1975). Cancer. Chemother. Rep. 6, 195–201.
Morré, D. J. (1971). Methods Enzymol. 22, 130–148.
Morré, D. J. (1994). J. Bioenerg. Biomembr. 26, 421–433.
Morré, D. J. (1995). Biochim. Biophys. Acta 1240, 201–208.
Morré, D. J., and Brightman, A. O. (1991). J. Bionerg. Biomembr. 23, 469–489.
Morré, D. J., and Morré, D. M. (1989). BioTechniques 7, 946–958
Morré, D. J., and Morré, D. M. (1995a). Protoplasma 184, 188–195.
Morré, D. J., and Morré, D. M. (1995b) J. Bioenerg. Biomembr. 27, 137–144.
Morré, D. J., and Reust, T. (1997). J. Bioenerg. Biomembr. 29, 281–289.
Morré, D. J., Crane, F. L., Erikson, L. C., Löw, H., and Morré, D. M. (1991). Biochim. Biophys. Acta 1057, 140–146.
Morré, D. J., Morré, D. M., and Wu, L.-Y. (1994). J. Bioenerg. Biomembr. 26, 137–142.
Morré, D. J., Morré D. M., Stevenson, J., MacKellar, W., and McClure, D. (1995a). Biochim. Biophys. Acta 1244, 133–140.
Morré, D. J., Wilkinson, F. E., Lawrence, J., Cho, N., and Paulik, M. (1995b). Biochim. Biophys. Acta 1236, 237–243.
Morré, D. J., Wu, L.-Y., and Morré, D. M. (1995c). Biochim. Biophys. Acta 1240, 11–17.
Morré, D. J., Merriman, R., Tanzer, L. R., Wu, L.-Y., Morré, D. M., and MacKellar, W. C. (1995d). Protoplasma 184, 203–208.
Morré, D. J., Chueh, P.-J., and Morré, D. M. (1995e). Proc. Natl. Acad. Sci. USA 92, 1831–1835.
Morré, D. J., Wilkinson, F. E., Kim, C., Cho, N., Lawrence, J., Morré, D. M., and McClure, D. (1996). Biochim. Biophys. Acta 1280, 197–206.
Moya-Camarena, S. Morré, D. J., and Morré, D. M. (1995) Protoplasma 188, 151–160.
Murphree, S. A., Cunningham, L. S., Hwang, K. M., and Sartorelli, A. C. (1976) Biochem. Pharmacol. 25, 1227–1231.
Myers, C. H., Mimmaugh, E. G., Yeh, G. C., and Simha, B. K. (1988). In Anthracyclines and Anthracycline-Based Anticancer Agents (Lown, J. W., ed.), Chap. XIV, Elsevier, Amsterdam.
Navas, P., Nowack, D. D., and Morré, D. J. (1989). Cancer Res. 49, 2146–2147.
Powis, G. (1989). Free Radical Biol. Med. 6, 63–101.
Rogers, K. E., and Tökes, Z. A. (1984). Biochem. Pharmacol. 33, 605–609.
Rogers, K. E., Forssen E. A., and Tökes, Z. A. (1982). Dev. Oncol. 10, 282–291.
Rogers, K. E., Carr, B. I., and Tökes, Z. A. (1983). Cancer Res. 43, 2741–2748.
Senter, P. D., Svensson, H. P., Schreiber, G. J., Rodriguez, J. L., and Vrudhala, V. M. (1995). Bioconjug. Chem. 6, 389–394.
Seymour, L. W., Ulbrich, K., Strohalm, J., Kopecek, J., and Duncan, R. (1990). Biochem. Pharmacol. 39, 1125–1131.
Seymour, L. W., Ulbrich, K., Steyger, P. S., Brereton, M., Subr, V., Strohalm, J., and Duncan, R. (1994). Br. J. Cancer 70, 636–641.
Silvestrini, R., DiMarco, A., and Dasdia, T. (1970). Cancer Res. 30, 966–973.
Silvestrini, R., Lenaz, L., Di Fronzo, G., and Sanfilippo, O. (1973). Cancer Res. 33, 2954–2958.
Sizensky, J. A., Barabas, K., and Faulk, W. P. (1992). Am. J. Reprod. Immunol. 27, 163–166.
Smith, P. K., Krohn, R. I., Hermanson, G. T., Mallia, A. K., Gartner, F. H., Provenzano, M. D., Fugimoto, E. K., Goeke, N. M., Olson, B. J., and Klenk, D. C. (1985). Anal. Biochem. 150, 70–76.
Sun, I. L., and Crane, F. L. (1984a) Biochem. Int. 9, 299–306.
Sun, I. L., and Crane, F. L. (1984b) Proc. Indiana Acad. Sci. 93, 267–274.
Sun, I. L., and Crane, F. L. (1985). Biochem. Pharmacol. 34, 617–622.
Sun, I. L., and Crane, F. L. (1990). In Oxidoreduction at the Plasma Membrane: Growth and Transport. I. Animals (Crane, F. L., Morré, D. J., and Löw, H., eds.), CRC Press, Boca Raton, Florida, pp. 257–280.
Sun, I. L., and Navas, P. (1986). In Redox Functions of the Eukarayotic Plasma Membrane (Ramirez, J. M., ed.). Publications Office CSIC, Madrid, pp. 67–89.
Sun, I. L., Crane, F. L., Chou, J. Y., Löw, H., and Grebing, C. (1983). Biochem. Biophys. Res. Commun. 116, 210–216.
Sun, I. L., Garcia-Canero, R., Liu, W., Toole-Simms, W., Crane, F. L., and Morré, D. J. (1987a). Biochem. Biophys. Res. Commun. 145, 467–473.
Sun, I. L., Navas, P., Crane, F. L., Morré, D. J., and Löw, H. (1987b). Biochem. Int. 14, 119–127.
Sun, I. L., Sun, E. E., Crane, F. L., Morré, D. J., and Faulk, W. P. (1992). Biochim. Biophys. Acta 1105, 84–88.
Tewey, K. M., Rowe, T. C., Yand, I., Halligan, B. C., and Liu, L. F. (1984). Science 226, 466–468.
Thornalley, P., Bannister, W., and Bannister, J. (1986). Free Rad. Res. Commun. 2, 163–171.
Tökes, Z. A., Rogers, K. E., and Rembaum, A. (1982). Proc. Natl. Acad. Sci. USA 79, 2026–2030.
Tritton, T. R., and Yee, G. (1982). Science 217, 248–250.
Vichi, P., and Tritton, T. R. (1989). Cancer Res. 49, 2679–2682.
Wingard, W. B., Tritton, T. R., and Eyler, A. K. (1985). Cancer Res. 15, 3520–3536.
Yeh, C. G., and Faulk W. P. (1984). Clin. Immunol. Immunopathol. 32, 1–11.
Yeh, C.-J. G., Taylor, C. G., and Faulk, W. P. (1984). Proteids Biol. Fluids 32, 441–444.
Young, R. C., Ozols, R. F., and Myers, C. E. (1981). N. Engl. J. Med. 305, 139–153.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Morré, D.J., Kim, C., Paulik, M. et al. Is the Drug-Responsive NADH Oxidase of the Cancer Cell Plasma Membrane a Molecular Target for Adriamycin?. J Bioenerg Biomembr 29, 269–280 (1997). https://doi.org/10.1023/A:1022414228013
Issue Date:
DOI: https://doi.org/10.1023/A:1022414228013